Advertisement

Drugs & Therapy Perspectives

, Volume 23, Issue 6, pp 1–4 | Cite as

Entecavir: a guide to its use in chronic hepatitis B

Drug and Profile Report

References

  1. 1.
    Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs 2006; 66(12): 1605–22PubMedCrossRefGoogle Scholar
  2. 2.
    Baraclude™ (entecavir): US prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2007 FebGoogle Scholar
  3. 3.
    European Medicines Agency (EMEA). Baraclude (entecavir): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Apr 5]
  4. 4.
    Bifano M, Yan JH, Xie J, et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir [abstract no. 1149]. Hepatology 2004 Oct; 40(4 Suppl. 1): 663Google Scholar
  5. 5.
    Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 Mar 9; 354(10): 1001–10PubMedCrossRefGoogle Scholar
  6. 6.
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 Mar 9; 354(10): 1011–20PubMedCrossRefGoogle Scholar
  7. 7.
    Yao G, Chen C, Lu W, et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients [abstract no. 519 plus poster]. 41st Annual Meeting of the European Association for the Study of the Liver; 2006 Apr 26–30; ViennaGoogle Scholar
  8. 8.
    Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006 Jun; 130(7): 2039–49PubMedCrossRefGoogle Scholar
  9. 9.
    de Man RA, Mutimer D, Gish RG, et al. Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022) [abstract no. P090]. J Clin Virol 2006 Jul; 36Suppl. 2: S89.CrossRefGoogle Scholar
  10. 10.
    Poordad F, Dieterich DT, Min AD, et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (STUDY ETV-027) [abstract no. T1851]. Gastroenterology 2006; 130(4 Suppl. 2): 848Google Scholar
  11. 11.
    Sherman M, Martin P, Lee WM, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) [abstract no. 478]. Gastroenterology 2006 Apr; 130(4 Suppl. 2): 765Google Scholar
  12. 12.
    Sollano J, Schiff E, Carrilho F, et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients [abstract no. 1153]. Hepatology 2004 Oct; 40(4 Suppl. 1): 665AGoogle Scholar
  13. 13.
    Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: 2005 update. Liver Int 2005 Jun; 25: 472–89PubMedCrossRefGoogle Scholar
  14. 14.
    Keeffe EB, Dieterich DT, Han S-HB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006 Aug; 4(8): 936–62PubMedCrossRefGoogle Scholar
  15. 15.
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34(6): 1225–41PubMedCrossRefGoogle Scholar
  16. 16.
    Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004; 19(1): 25–37PubMedCrossRefGoogle Scholar
  17. 17.
    Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 2682–95PubMedCrossRefGoogle Scholar
  18. 18.
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004 Apr; 39(3): 857–61PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations